Advanced renal cell carcinoma and triple negative breast cancer (TNBC) are malignancies without effective therapeutics currently. Ursolic acid (UA) has been previously reported to have anti-cancer effects in multiple solid tumors. In order to develop more potent anti-cancer reagents, FZU-03,010 based on the chemical structure of UA were synthesized. The results demonstrated that, compared with UA, FZU-03,010 could suppress renal cancer cell 786-0 and TNBC cell HCC1806 cell viability more potently. Furthermore, FZU-03,010 could induce G1 cell cycle arrest and cell apoptosis more efficiently than UA. FZU-03,010 could also inhibit signal transducer and activator of transcription 3 activation, induce the expression of cell cycle-dependent kinase inhibitors (p21 and p27) and promote cell apoptosis. In conclusion, our results suggest that the UA derivative FZU-03,010 is more potent in inhibiting cancer cell survival, and FZU-03,010 has the potential to be developed as a therapeutic for renal cell cancers and TNBCs.
Introduction
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, responsible for~90%-95% of cases. The incidence of RCC has increased continuously for the last decades worldwide. RCC patients are usually detected in physical examination without obvious symptoms [1] and~30% of newly diagnosed patients have already presented local invasion or have progressed to Stage IV with distant metastases. Mortality rate of metastatic RCC (mRCC) patients in most developing countries is still rising [2] . About 25% of RCC patients with surgical resection for localized carcinoma eventually relapsed. Epidemiological studies show that patients with distant metastases generally have poor prognosis, with a 5-year survival rate <10% [3] . The standard treatment for patients with earlystage renal cancer is open radical nephrectomy; however, there are no effective therapeutics for advanced RCC, and mRCC patients are usually refractory or intolerant to immunotherapy currently [4] .
Breast cancer is one of the most common malignancies among women [5] , which is a highly complicated disease with large interand intra-tumoral heterogeneity. The triple negative (estrogen receptor ERα negative, progesterone receptor PR negative and human epithelial growth factor receptor 2 Her2 negative) subtype breast cancer (TNBC) has the poorest clinical outcome [6] . TNBC accounts for 15%-25% of breast tumors and it is usually insensitive to traditional endocrine therapies or Her2 targeted therapies, resulting in poorer prognosis comparing to other breast cancer subtypes. Additionally, high rate of recurrence also exacerbates TNBC's prognosis [7] .
Considering the poor prognosis and lacking of effective therapeutics for mRCC and TNBC, it is urgent to identify effective and potent therapeutics. It is well-known that natural products play a dominant role in drug discovery, and around 60% approved anticancer drugs origin from the natural resources. Ursolic acid (UA), which was previously found to have anti-tumor effects, is a pentacyclic triterpenoid widely existing in a large variety of natural resources, such as rosemary (Rosmarinus officinalis), apples (Malus domestica), loquat (Eriobotrya japonica) and basil (Ocimum sanctum) [8, 9] . UA has been shown to exhibit anti-bacterial, anti-viral, hepatoprotective, and immunomodulatory activities [10] . Recent studies revealed that UA inhibits tumor cell proliferation and induces apoptosis via modulating multiple signaling pathways, such as promoting β-catenin degradation, suppressing FoxM1 expression, targeting signal transducer and activator of transcription 3 (STAT3), Jun N-terminal kinase, and AKT serine/threonine kinase 1/nuclear factor kappa B subunit signaling pathways [11] [12] [13] . Although UA inhibits cancer cell survival, the half maximal inhibitory concentration (IC 50 ) of UA is relatively high and the efficacy and functional mechanisms of UA in RCC and TNBC have not been fully elucidated. To develop more potent anti-cancer reagents, we designed and synthesized FZU-03,010 from the lead compound UA, and compared the effects of UA and its derivative FZU-03,010 on a RCC and a TNBC cell line.
It was found that both UA and its derivative FZU-03,010 had anti-tumor effects in 786-0 and HCC1806 cell lines. However, FZU-03,010 induced apoptosis and cell cycle G0/G1 phase arrest more effectively than UA. FZU-03,010 suppressed the phosphorylation of STAT3 at much lower dosages than UA. Taken together, our data suggest that the UA derivative, FZU-03,010 may serve as a potential therapeutic drug for mRCC and TNBC.
Materials and Methods

Cell lines and drugs
The RCC cell line 786-0 and the TNBC cell line HCC1806 were purchased from the American Type Culture Collection (ATCC, Manassas, USA). 786-0 and HCC1806 cells were cultured in RPMI-1640 medium (HyClone, Logan, USA) supplemented with 5% fetal bovine serum. All cells were maintained at 37°C with 5% CO 2 in a humidified atmosphere. UA was purchased from Sigma-Aldrich (St Louis, USA), and the UA derivative was synthesized based on the chemical structure of UA.
Antibodies
The anti-poly ADP-ribose polymerase (PARP), p21, p-STAT3, and STAT3 antibodies were purchased from Cell Signaling Technology (Danvers, USA). The anti-p27 antibody was from Becton Dickinson (San Diego, USA). The anti-Caspase-3, cleaved Caspase-3, Caspase-7, and cleaved Caspase-7 antibodies were from Imagenex (San Diego, USA). The anti-β-actin antibody was from Sigma-Aldrich.
Cell viability assay
Cell viability was measured by Sulforhodamine B (SRB) assay. Briefly, 786-0 and HCC1806 cells were plated in 48-well plates at 2×10 4 or 3×10 4 cells/well, respectively. Twenty-four hours later, the cells were treated with either FZU-03,010 or UA at the indicated dosage for another 48 h. The vehicle dimethyl sulphoxide (DMSO) was used as the negative control. The cells were then fixed with 10% trichloroacetic acid for 60 min at room temperature (RT) followed by washing with deionized water five times. The cells were stained with 0.4% (W/V) SRB (Sigma) for 15 min at RT, followed by five times wash with 1% acetic acid. Finally, 10 mM Tris base was added to dissolve the dye and the optical densities at 530 nm were measured on a spectrophotometric plate reader (Bio-Tek, Vermont, USA).
Cell cycle analysis 
Apoptosis analysis
Cells were trypsinized with 0.25% trypsin-ethylenediaminetetraacetic acid (GIBCO, Grand Island, USA) and collected with complete cell culture medium. The cells were washed with 1×PBS and stained with anti-Annexin V antibody and PI according to manufacturer's protocol (eBioscience, San Diego, USA). Briefly, the cells were washed with 1×binding buffer, followed by staining with fluorescein isothiocyanatelabeled Annexin V in dark for 30 min at RT. Following Annexin V staining, the cells were washed with 1×binding buffer twice, stained with PI, and analyzed on the Accuri C6 flow cytometer (BD Bioscience).
Western blot analysis
Cell lysates were prepared as described previously [14] . Protein concentration was measured using protein assay kit (Bio-Rad, Hercules, USA), and 40 μg protein samples were subject to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted onto polyvinylidene fluoride membranes. Membranes were blocked with 5% non-fat milk for 1 h at RT and then incubated with the specific primary antibodies at 4°C overnight. After being washed with PBS containing 0.1% Tween-20 (PBST), the membranes were incubated with horseradish peroxidase conjugated secondary antibodies (Jackson ImmunoResearch Laboratory, West Grove, USA) for 1 h at RT. The membranes were washed with PBST and incubated with Western Lighting Chemiluminescence Reagent Plus (PerkinElmer Life Sciences, Shelton, USA) and then the targeted proteins were visualized on an ImageQuant LAS4000 Biomolecular imager (GE, New York, USA).
Statistical analysis
All experiments were repeated at least three times to ensure accuracy. When appropriate, the data were pooled and expressed as the mean ± standard deviation and analyzed by student's t-test. P < 0.05 were considered as significant.
Results
FZU-03,010 suppresses cancer cell viability at lower concentrations than UA
In order to develop more potent anti-cancer reagents, FZU-03,010 was synthesized based on the chemical structure of UA. As shown in Fig. 1A , FZU-03,010 with a nitrogen-containing heterocyclic scaffold and the privileged fragment at the 28-position displayed markedly enhanced aqueous solubility. The anti-cancer effects of FZU-03,010 and UA were first tested in renal cancer cell line 786-0 and TNBC cell line HCC1806 using SRB assays. As shown in Fig. 1B , both cell lines were treated with either FZU-03,010 or UA at indicated concentrations for 48 h. It was found that both FZU-03,010 and UA could suppress cell viability in a dosagedependent manner in 786-0 and HCC1806 cell lines. However, FZU-03,010 reduced cell viability at much lower concentrations than UA. The IC 50 values of FZU-03,010 in 786-0 or HCC1806 were 3.2 and 7.0 μM, respectively, which were much lower than those of UA (7.0 and 15.4 μM, respectively). Overall, FZU-03,010 reduced 786-0 or HCC1806 cancer cell viability much more effectively than UA.
FZU-03,010 causes cell cycle G0/G1 arrest in 786-0 and HCC1806 cells Both cell growth inhibition and cell death result in the reduction of cell viability. To determine the reason that FZU-03,010 reduced cell viability more than UA, we first tested whether FZU-03,010 inhibited cell growth through affecting cell cycle progression. As shown in Fig. 2, FZU-03 ,010 could induce 786-0 cell cycle arrested in G0/ G1 phase with limited decrease in S and/or G2/M phases at 2.5 and 5 μM. In HCC1806 cells, FZU-03,010 treatment also caused cell cycle G0/G1 arrest (2.5 μM) and reduction of cell proportion in G2/M phase (2.5 and 5 μM). However, UA did not affect the cell cycle progression in either 786-0 or HCC1806 cell lines at 5 μM. These results implicated that FZU-03,010 is more potent than UA in inhibiting cell cycle progression.
FZU-03,010 induces apoptosis in 786-0 and HCC1806 cells
Since FZU-03,010 induces cell cycle arrest in 786-0 and HCC1806, whether FZU-03,010 affects apoptosis was further tested. Both cell lines were treated with either FZU-03,010 or UA at indicated concentrations for 24 h (Fig. 3) , and the proportion of cells undergone apoptosis was detected using Annexin V staining. The morphology of the cells was observed before the flow cytometry analysis. As shown in Fig. 3A , with the increase of drug concentration, the cells become more round and scattered. Flow cytometry analysis showed that FZU-03,010 significantly induced apoptosis in both 786-0 and HCC1806 cell lines compared with UA. Docetaxel (DTX) was used as the positive control. The ratio of Annexin V positive cells were increased in a dose-dependent manner (Fig. 3B,C) . To further confirm these results, several apoptosis markers were examined using western blot analysis. Indeed, the cleavage of Caspase-3, Caspase-7, and PARP was increased after UA and FZU-03,010 treatment in both cell lines (Fig. 4) . Consistently, FZU-03,010 induced more cleavage of apoptosis markers than UA at the same concentration. These results implicated that FZU-03,010 is more potent than UA in inducing apoptosis.
FZU-03,010 suppresses the STAT3 activation more potently than UA in 786-0 and HCC1806 cells Aberrant activation of STAT3 has been suggested to be strongly correlated with the progression of several solid malignancies, and inhibition of STAT3 activation induces apoptosis in cancer cells [15] [16] [17] [18] . It has been reported that UA suppresses cancer cell proliferation and promotes apoptosis via inhibiting STAT3 pathway [9, 12] . Therefore, we tested whether FZU-03,010 also inhibits the STAT3 activation in 786-0 and HCC1806 cells. Both cell lines were treated with FZU-03,010 or UA at indicated concentrations for 48 h. The STAT3 and p-STAT3 levels were detected using western blot analysis. As shown in Fig. 4 , UA inhibited phosphorylation of STAT3 in a dose-dependent manner as expected. Interestingly, FZU-03,010 decreased p-STAT3 level at much lower concentrations than UA. STAT3 has been shown to down-regulate p27 and p21 [19, 20] . In our results, with the decrease of p-STAT3 levels, the p21 and p27 expression levels increase gradually. Taken together, both FZU-03,010 and UA efficiently suppress STAT3 phosphorylation; however, FZU-03,010 is more potent than UA. These results suggest that FZU-03,010 may induce cell cycle arrest and apoptosis via the STAT3 pathway.
Discussion
Both mRCC and TNBC are malignancies without effective therapeutics currently. These cancers are resistant to most chemotherapy used clinically. Thus, it is important and urgent to develop new and effective methods for the treatment of mRCC and TNBC.
UA, a pentacyclic triterpenoid which widely exists in a large variety of natural resources, has been reported to have anti-tumor effects in multiple solid malignancies, such as inducing apoptosis, inhibiting cell proliferation, and metastasis through regulating several signaling pathways [12, [21] [22] [23] [24] [25] [26] . However, the role of UA in TNBC and mRCC cells has not been fully addressed. To test whether UA has anti-tumor effects in TNBC and mRCC cells and to optimize the anti-tumor effects of UA, we tested the effects of UA and its derivative, FZU-03,010 on both mRCC cell line 786-0 and TNBC cell line HCC1806. Our results revealed that although both compounds reduced cell viability, FZU-03,010 reduced cancer cell viability with a much lower IC 50 than UA. Since the loss of cell viability could be caused by cell growth inhibition and/or cell death increase, we then investigated the effects of FZU-03,010 on cell cycle progression and apoptosis compared with UA. FZU-03,010 was more potent in inducing G1 cell cycle arrest and apoptosis in both 786-0 and HCC1806 cell lines. Furthermore, FZU-03,010 suppressed the STAT3 activation, promoted Caspase-3/7 and PARP cleavage, and induced cell cycledependent kinase inhibitors (p21 and p27) expression more effectively than UA in both 786-0 and HCC1806 cancer cell lines.
As a compound with anti-tumor activities, previous studies proved that UA induces apoptosis in various human cancers such as liver cancer [27] , gastric cancer [28] , bladder cancer [29] , colorectal cancer [9] , lung cancer [30] pancreatic cancer [31] , and breast cancer [32, 33] . Previous study revealed that UA arrests cell cycle in G1 phase and induces apoptosis. In this study, we confirmed that UA induced cell cycle arrest and apoptosis in both tested cell lines; however, FZU-03,010 functioned more potently than UA.
STAT3 is localized in the cytoplasm in an inactive form, and stimulation by diverse cytokines as well as growth factors can trigger its phosphorylation and dimerization, which eventually causes its nuclear translocalization and activation. In both normal and malignant tissues, STAT3 plays a key role in regulating cell proliferation, survival, angiogenesis, and metastasis. Aberrant constitutive STAT3 activation has been reported to be correlated with the progression of a variety of cancers. Moreover, high expression of STAT3 has been associated with a poor prognosis in many cancers such as colorectal cancer [34, 35] , gastric cancer [36] , liver cancer [37] , and lung cancer [38] . Thus, pharmacological inhibitors of STAT3 have a potential in prevention and therapy of cancers [39] [40] [41] [42] [43] [44] [45] . Abrogation of the STAT3 signaling cascade has been found to cause growth inhibition, apoptosis, and autophage, as well as to impair tumor growth in multiple in vitro and in vivo models, such as prostate cancer [41] , osteosarcoma [46] , hepatosarcoma [47] , and lung cancer cells [48, 49] .
Our results suggest that the anti-cancer molecular mechanisms of compound FZU-03,010 may be through suppressing the STAT3 signaling pathway. Indeed, UA (at 5 µM) could down-regulate the level of p-STAT3, up-regulate STAT3's downstream targets, p21 and p27, expression, and promotes the cleavage of PARP, Caspase-3, and Caspase-7; however, FZU-03,010 showed the same effects at lower concentrations (1.25 and 2.5 µM). These results suggest that FZU-03,010 is likely to inhibit 786-0 and HCC1806 cell survival through suppressing the STAT3 signaling. Besides STAT3, there may be other pathways involved in FZU-03,010's anti-tumor functions, which needs to be further investigated.
In conclusion, we found that both UA and its derivative FZU-03,010 have anti-tumor effects in 786-0 and HCC1806 cell lines. FZU-03,010 is a more potent cytotoxic derivative, which exhibits stronger anti-cancer effects in terms of inducing cell cycle arrest and promoting apoptosis than its parent compound UA. We also provided evidence that FZU-03,010 might function through suppressing STAT3. Therefore, our results suggest that FZU-03,010 may be a promising candidate as a novel mRCC and TNBC therapeutics. 
